9/4/2024

Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides

  • Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcar
  • Macro Biologics, Inc. develops large molecule biologics which can alleviate or improve skin issues and prevent wound infections
  • Beiersdorf also joins Macro Biologics, Inc. as an investor through its Oscar & Paul Corporate Venture Capital Unit

Hamburg, September 4, 2024 – Beiersdorf and Macro Biologics, Inc. have entered a multi-year partnership to collaborate on the development of biodegradable antimicrobial peptides with broad application possibilities in skin care and healthcare. At the same time, Beiersdorf joins Macro Biologics as an investor through its Oscar & Paul Corporate Venture Capital Unit. By bringing Macro Biologics’ advanced technology in antimicrobial research into the skin care and healthcare ecosystem, Beiersdorf further underlines its ambition to continuously deliver transformative and sustainable innovations to its consumers.

The collaboration in this dynamic research field will focus on the utilization of Macro Biologics’ highly effective antimicrobial “Amicidins” in Beiersdorf’s innovative product and formula development. Amicidins are effective against a wide variety of bacteria, which means they can help to alleviate or improve skin conditions and are moreover designed for early, local application in the prevention of wound infections. The joint objective is to create highly effective, safe, and sustainable solutions for a variety of application areas across Beiersdorf’s brand portfolio, primarily in dermatological skin care and healthcare.

“Through our collaboration with Macro Biologics, we further enhance Beiersdorf’s innovation power in line with our ‘Win with Care’ strategy, as well as our ambition to continue to lead in Climate Care,” emphasized Dr. Gitta Neufang, Corporate Senior Vice President Global R&D of Beiersdorf. “We are excited to have found an outstanding partner in this promising field of antimicrobial peptides, who shares our visionary innovation drive. We are eager to jointly bring Macro Biologics’ advanced technology into the world of skin care and healthcare.”

“We are very pleased to partner with Beiersdorf, a global powerhouse in skin care and healthcare,” said Dr. Michael Bevilacqua, CEO and CSO of Macro Biologics. “For Macro, this collaboration is a perfect fit, both from a research and business perspective. Beiersdorf’s deep expertise in product formulation, development, and commercialization will empower Amicidins to improve the lives of people in a variety of settings. This partnership is based on shared principles, as we both strive to create sustainable value for people and the environment.”

Press Contact

Anke Schmidt
Vice President Corporate Communications & Government Relations

Beiersdorf AG
Beiersdorfstraße 1-9
22529 Hamburg, Germany

Phone: +49 (0) 40 - 4909 2001

 

Contact Us